StockUS listing USKLRANASDAQHealthcareValue Trap

Kailera Therapeutics, Inc. Common Stock(KLRA) Stock Analysis | Healthcare

USD --+0.00%
Reward45Moderate
Risk24Low
25%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.43Bn
Reward Ratingⓘ45 Moderate reward assessment · 25% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ24 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on KLRA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Kailera Therapeutics, Inc. Common Stock?

operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

AI Brief Pro

The brief on Kailera Therapeutics, Inc. Common Stock

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Kailera Therapeutics, Inc. Common Stock?

operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.43B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (45)
Company Information
SectorHealthcare
IndustryBiotechnology
BetaN/A
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
0
520,421,876 shares
$326.8M
9-12months
0
0